Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study

Table 2

Parameters describing glucose variability in participants being treated with combination therapy or IDegLira.

	IDeg+DPP-4i	IDegLira	value
MAGE (mg/dL)	74.9 (60.3, 97.7)	64.8 (52.0, 78.2)	<0.05^†
value (mg/dL)			<0.01
MAG (mg/dL)			<0.01
MODD (mg/dL)			<0.05
ADRR (mg/dL)			<0.05
J-index	6776.9 (5553.8, 10510.1)	4984.3 (4412.7, 8123.0)	<0.01^†
CONGA (mg/dL)			<0.01
HBGI			<0.01
24 h mean glucose (mg/dL)			<0.01
CV (%)			0.54
SD (mg/dL)	28.2 (18.8, 36.6)	21.9 (18.0, 23.7)	<0.05^†
TBR (%)	0.5 (0, 1.4)	2.6 (0, 5.5)	<0.05^†
TIR (%)	94.3 (69.0, 99.0)	94.5 (85.4, 97.4)	0.56^†
TAR (%)	2.3 (0, 20.8)	0 (0, 5.2)	<0.05^†

Values are expressed as or median (interquartile range). value of IDeg+DPP-4i vs. IDegLira. ^†Wilcoxon signed-rank test was applied to the factors: MAGE, J-index, SD, TBR, TIR, and TAR. MAGE: mean amplitude of glycemic excursions; MAG: mean absolute glucose; MODD: mean of daily difference; ADRR: average daily risk range; CONGA: continuous overall net glycemic action; HGBI: high blood glucose index; CV: coefficient of variation; SD: standard deviation; TBR: time below target glucose range; TIR: the target glucose range; TAR: time above target glucose range.